Adiponectin (ACRP30; AdipoQ) is a promising biomarker of insulin resistance and type 2 diabetes mellitus (T2DM) but also as a potential target for management of the metabolic syndrome. It is a very robust marker that is not prone to degradation or acute inflammatory challenges, is present in relatively high concentrations in the peripheral circulation, and can be collected by a variety of methods.
The benefits of using adiponectin assays in clinical settings include:
- prediction of risk of diabetes and metabolic status
- providing a tool to monitor metabolic improvements
Adiponectin exerts anti-atherogenic & anti-inflammatory properties and may be important as a biomarker for obesity-related cardiovascular disease (CVD). New findings showed urinary adiponectin excretion as an independent new biomarker of microvascular and macrovascular damage in T2DM and suggested it as a very promising tool for early cardiovascular disease risk assessment. Adiponectin serum level was also described as a good biomarker of colorectal adenoma, this being related to the positive correlation between obesity and increased risk of cancer at various sites (colorectal, breast, prostate and endometrium).
Adiponectin (human) ELISA Kit
Adiponectin (human) Competitive ELISA Kit
Other species available include rhesus monkey, macaque (AG-45A-0003).
No comments:
Post a Comment